secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211918
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility
--------------------------------------------------------------------------------

- Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.
- Cash, cash equivalents, and investments $206.5M; runway expected through at least 2027.
- Discontinued Phase 2 PROGRESS-AD trial of nivisnebart (AL101) in early AD after futility analysis.
- ABC platform progress: AL037/AL137 (anti-Aβ) targeting IND in Q1 2027; AL050 (GCase ERT for PD) preclinical; AL164 (Tau siRNA) in IND-enabling studies.
- R&D expenses decreased to $17.9M from $33.6M; G&A $8.1M from $14.7M due to workforce reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/0001193125-26-211918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526211918/alec-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer